Mivacurium: a Review
- 73 Downloads
Purpose of Review
Mivacurium is a short-acting non-depolarizing neuromuscular-blocking agent (NMBA) which has recently been re-released onto the US market. This review provides a brief overview about the pharmacology of mivacurium and discusses its use in recent clinical practice.
Mivacurium has been reported to be especially useful in the pediatric population, especially for shorter cases, and infusions can be used for longer cases without inducing tachyphylaxis. As it is rapidly metabolized by pseudocholinesterase (PChE), mivacurium does usually not require a specific reversal agent to offset its actions at the end of surgery. Especially for use in short cases, this makes it a potentially advantageous alternative to the use of other NMBA. However, deficiencies in PChE as well as old age and some drug interactions can be associated with prolonged neuromuscular blockade. The rapid administration of higher doses may provoke significant histamine release leading to hemodynamic compromise.
Despite other NMBA being available on the market and its side effects, mivacurium may still be a useful agent in short cases, particularly in the pediatric population.
KeywordsMivacurium Neuromuscular-blocking agent Pseudocholinesterase deficiency Cardiovascular instability Drug interactions
Compliance with Ethical Standards
Conflict of Interest
Lisa S. Molloy declares that she has no conflict of interest. Thomas Ledowski has received speaker’s honoraria and is supported by a non-related research grant from MSD, the manufacturer or rocuronium and sugammadex.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Mivacron Injection. The Electronic Medicines Compendium. 2017. https://www2.medicines.org.uk/emc/medicine/757 Accessed 10th Oct 2017.
- 2.Smith S, Scarth E, Asada M. Mivacurium In. Drugs in anaesthesia and intensive care 4th Ed. 2011 Oxford. Oxford University Press 2011 pgs 232–233.Google Scholar
- 5.• Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired a and drug influences. AANA Jnl. 2010;78(4):313–20. This article is a comprehensive review of the genetics, drug interactions, and conditions associated with pseudocholinesterase deficiency Google Scholar
- 8.Alibhai M, Wheatley S. Mivacurium, fixation error and human factors. HSOA J Anaes Clin Care. 2017;4:20–1.Google Scholar
- 14.Tercan M, Mercanoglu EE, Turker G, Nur Kaya F, Yavascoaglu B, Ozarda Y, et al. Do metoclopromide and onadsetrone alter mivacurium-induced neuomuscular blockade?—a randomised trial. Rev Bras Anastesiol. 2014;64:34–9.Google Scholar
- 18.• Plaud B, Marty J, Debaene B, Meistelman C, Pellissier D, LePage JY, et al. The cardiovascular effects of mivacurium in hypertensive patients. Anaesth Analg. 2002;95:379–84. A study which compares hypertensive and normotensive and the effect of the rates of mivacurium boluses which is highly relevant to clinical practice. Google Scholar
- 19.Erol D. Bronchospasm in a pediatric adenoidectomy case. Int J Anesth. 2014;11:1.Google Scholar
- 29.Soto RG, Dunipace D. Mivacurium: return of a drug seeking an indication. ASA Monitor. 2017;81:30–1.Google Scholar